JP2015078199A5 - - Google Patents

Download PDF

Info

Publication number
JP2015078199A5
JP2015078199A5 JP2014231450A JP2014231450A JP2015078199A5 JP 2015078199 A5 JP2015078199 A5 JP 2015078199A5 JP 2014231450 A JP2014231450 A JP 2014231450A JP 2014231450 A JP2014231450 A JP 2014231450A JP 2015078199 A5 JP2015078199 A5 JP 2015078199A5
Authority
JP
Japan
Prior art keywords
cancer
diseases
mek
heptane
ethyl acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014231450A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015078199A (ja
JP6309880B2 (ja
Filing date
Publication date
Priority claimed from US11/830,733 external-priority patent/US8101799B2/en
Application filed filed Critical
Publication of JP2015078199A publication Critical patent/JP2015078199A/ja
Publication of JP2015078199A5 publication Critical patent/JP2015078199A5/ja
Application granted granted Critical
Publication of JP6309880B2 publication Critical patent/JP6309880B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2014231450A 2007-07-30 2014-11-14 Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法 Expired - Fee Related JP6309880B2 (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US11/830,733 US8101799B2 (en) 2005-07-21 2007-07-30 Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US11/830,733 2007-07-30
US3446408P 2008-03-06 2008-03-06
US3446608P 2008-03-06 2008-03-06
US61/034,466 2008-03-06
US61/034,464 2008-03-06
US4488608P 2008-04-14 2008-04-14
US61/044,886 2008-04-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010520118A Division JP2010535232A (ja) 2007-07-30 2008-07-28 Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017018477A Division JP2017125021A (ja) 2007-07-30 2017-02-03 Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法

Publications (3)

Publication Number Publication Date
JP2015078199A JP2015078199A (ja) 2015-04-23
JP2015078199A5 true JP2015078199A5 (cg-RX-API-DMAC10.html) 2016-05-26
JP6309880B2 JP6309880B2 (ja) 2018-04-11

Family

ID=40304796

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010520118A Pending JP2010535232A (ja) 2007-07-30 2008-07-28 Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法
JP2014231450A Expired - Fee Related JP6309880B2 (ja) 2007-07-30 2014-11-14 Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法
JP2017018477A Pending JP2017125021A (ja) 2007-07-30 2017-02-03 Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2010520118A Pending JP2010535232A (ja) 2007-07-30 2008-07-28 Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017018477A Pending JP2017125021A (ja) 2007-07-30 2017-02-03 Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法

Country Status (22)

Country Link
EP (1) EP2184984A4 (cg-RX-API-DMAC10.html)
JP (3) JP2010535232A (cg-RX-API-DMAC10.html)
KR (3) KR20100092424A (cg-RX-API-DMAC10.html)
CN (2) CN103479604B (cg-RX-API-DMAC10.html)
AP (1) AP2817A (cg-RX-API-DMAC10.html)
AU (2) AU2008282338B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0815659A2 (cg-RX-API-DMAC10.html)
CA (1) CA2693390C (cg-RX-API-DMAC10.html)
CO (1) CO6470808A2 (cg-RX-API-DMAC10.html)
CR (1) CR11244A (cg-RX-API-DMAC10.html)
DO (1) DOP2010000045A (cg-RX-API-DMAC10.html)
EA (2) EA032294B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP109910A (cg-RX-API-DMAC10.html)
HN (1) HN2010000203A (cg-RX-API-DMAC10.html)
IL (1) IL203296A (cg-RX-API-DMAC10.html)
MA (1) MA31881B1 (cg-RX-API-DMAC10.html)
MX (1) MX2010001244A (cg-RX-API-DMAC10.html)
NZ (1) NZ582929A (cg-RX-API-DMAC10.html)
PH (1) PH12015501914A1 (cg-RX-API-DMAC10.html)
SV (1) SV2010003469A (cg-RX-API-DMAC10.html)
TN (1) TN2010000049A1 (cg-RX-API-DMAC10.html)
WO (1) WO2009018233A1 (cg-RX-API-DMAC10.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
CN102131771A (zh) * 2008-04-14 2011-07-20 阿迪生物科学公司 组合物及其制备和使用方法
BRPI0918526B1 (pt) * 2008-09-09 2022-02-15 F. Hoffmann-La Roche Ag Forma cristalina polimórfica anidra de acil sulfonamidas, seu processo de preparação, uso e composição farmacêutica que a compreende
NZ592338A (en) 2008-09-26 2012-11-30 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
SG174272A1 (en) * 2009-03-11 2011-10-28 Ardea Biosciences Inc Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers
UY32486A (es) * 2009-03-11 2010-10-29 Ardea Biosciences Inc Tratamiento del cáncer de páncreas
ES2534358T3 (es) 2009-10-13 2015-04-21 Allomek Therapeutics, Llc Inhibidores novedosos de MEK útiles en el tratamiento de enfermedades
WO2011047788A1 (en) * 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted benzosulphonamides
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
CN102649773A (zh) * 2011-02-23 2012-08-29 苏州波锐生物医药科技有限公司 氨基芳香烃类化合物及其在制备抗恶性肿瘤药物中的用途
EA201391587A1 (ru) * 2011-04-28 2014-08-29 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч Комбинированная терапия на основе hsp90
AR086553A1 (es) * 2011-05-27 2014-01-08 Bayer Ip Gmbh Sintesis quiral de n-{3,4-difluoro-2-[(2-fluoro-4-yodofenil)amino]-6-metoxifenil}-1-[2,3-dihidroxi-propil]ciclopropano sulfonamidas
JP2015502958A (ja) * 2011-12-09 2015-01-29 オンコメッド ファーマシューティカルズ インコーポレイテッド がんの処置のための併用療法
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
BR112014029338A2 (pt) * 2012-05-31 2017-06-27 Bayer Pharma AG biomarcadores para determinação da resposta eficaz dos tratamentos de pacientes com carcinoma hepatocelular (hcc)
MX348290B (es) 2012-06-04 2017-06-05 Pharmacyclics Llc Formas cristalinas de un inhibidor de tirosina quinasa de bruton.
FI3702351T3 (fi) * 2012-10-19 2024-01-24 Array Biopharma Inc MEK-inhibiittorin käsittävä koostumus
CA2890238A1 (en) 2012-11-02 2014-05-08 Merck Patent Gmbh Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
EP2848246A1 (en) 2013-09-13 2015-03-18 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib
EP3046557A1 (en) 2013-09-20 2016-07-27 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
AU2015306683B2 (en) 2014-08-25 2021-11-25 Societe Des Produits Nestle S.A. Egg protein formulations and methods of manufacture thereof
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
BR112019026483A2 (pt) * 2017-06-16 2020-07-14 Beta Pharma, Inc. formulação farmacêutica de n-(2-(2-(dimetilamina)etoxi)-4-metoxi-5-((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amina)fenil)acrilamida e seus sais
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
JP2022551439A (ja) * 2019-10-04 2022-12-09 スミトモ ファーマ オンコロジー， インコーポレイテッド Ａｘｌ阻害薬製剤
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
CN118834328B (zh) * 2024-07-02 2025-09-16 江苏海洋大学 金属蛋白酶9抗原决定基印迹纳米颗粒的制备方法及应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
JP2575590B2 (ja) * 1992-07-31 1997-01-29 塩野義製薬株式会社 トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法
ES2177868T3 (es) * 1992-08-25 2002-12-16 Searle & Co Hidroxietilaminosulfonamidas de alfa- y beta-aminoacidos utiles como inhibidores de proteasas retroviricas.
US7115632B1 (en) * 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
ES2249060T3 (es) * 1999-01-13 2006-03-16 Warner-Lambert Company Llc Diarilaminas sustituidas con 1-heterociclo.
GB0003224D0 (en) * 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
WO2003026574A2 (en) * 2001-09-24 2003-04-03 Au Jessie L-S Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
EP1534262A1 (en) * 2002-07-17 2005-06-01 Titan Pharmaceuticals, Inc. Combination of chemotherapeutic drugs for increasing antitumor activity
ES2369535T3 (es) * 2002-07-30 2011-12-01 Eterna Zentaris Gmbh Uso de alquilfosfocolinas en combinación con medicamentos antitumorales.
WO2006110811A1 (en) * 2005-04-12 2006-10-19 Elan Pharma International Limited Nanoparticulate quinazoline derivative formulations
CN101198582A (zh) * 2005-04-22 2008-06-11 橘生药品工业株式会社 4’－{2－[(1s,2r)－2－羟基－2－(4－羟基苯基)－1－甲基乙氨基]乙氧基}－3－异丙基－3’，5’－二甲基联苯羧酸盐酸盐的结晶多形
ES2481402T3 (es) * 2005-07-21 2014-07-30 Ardea Biosciences, Inc. Inhibidores de N-(arilamino)sulfonamida de MEK
JP2007099763A (ja) * 2005-09-08 2007-04-19 Toyama Chem Co Ltd ピペラシリンナトリウム・１水和物の新規な結晶及びその製造方法
TW200800150A (en) * 2005-12-21 2008-01-01 Organon Nv Compounds with medicinal effects due to interaction with the glucocorticoid receptor

Similar Documents

Publication Publication Date Title
JP2015078199A5 (cg-RX-API-DMAC10.html)
JP2018520205A5 (cg-RX-API-DMAC10.html)
CN115244058A (zh) 嘧啶并二环类衍生物、其制备方法及其在医药上的应用
HRP20192209T1 (hr) Derivati benzofurana, postupci njihove pripreme i njihova uporaba u medicini
RU2016130095A (ru) Конъюгат анти-trop2 антитело-лекарственное средство
JP2017507175A5 (cg-RX-API-DMAC10.html)
JP2019518766A5 (cg-RX-API-DMAC10.html)
JP2013525363A5 (cg-RX-API-DMAC10.html)
RU2016118753A (ru) Производные пиридилкетона, способ их получения и их фармацевтическое применение
HRP20180499T1 (hr) Spojevi i postupci za modulaciju kinaze, te odgovarajuće indikacije
RU2019101220A (ru) Кристаллические формы соединения триазолопиримидина
JP2013525458A5 (cg-RX-API-DMAC10.html)
JP2019522055A5 (cg-RX-API-DMAC10.html)
HRP20140486T1 (hr) Postupci sinteze spojeva spirooksindola
ME02452B (me) Sredstva za induciranje apoptoze namijenjena liječenju raka i imunih i autoimunih bolesti
RU2017136715A (ru) Производное имидазоизоиндола, способ его получения и медицинское применение
JP2014534269A5 (cg-RX-API-DMAC10.html)
JP2022071077A5 (cg-RX-API-DMAC10.html)
RU2014101626A (ru) Полиморфы 2-амид 1-({4-метил-5-[2-(2, 2, 2-трифтор-1, 1-диметил-этил)-пиридин-4-ил]тиазол-2-ил}амида) (s)-пирролидин-1, 2-дикарбоновой кислоты
CA2796744A1 (en) Synthetic metabolites of fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
JP2016528273A5 (cg-RX-API-DMAC10.html)
RU2016133731A (ru) Функционализованные соединения бензопирана и их применение
JP2013523680A5 (cg-RX-API-DMAC10.html)
JP2016539985A5 (cg-RX-API-DMAC10.html)
JP2016504325A5 (cg-RX-API-DMAC10.html)